Free Daily Headlines :

  • COVID-19
  • Vaccine Info
  • Money
  • Politics
  • Education
  • Health
  • Justice
  • More
    • Environment
    • Economic Development
    • Gaming
    • Investigations
    • Social Services
    • TRANSPORTATION
  • Opinion
    • CT Viewpoints
    • CT Artpoints
DONATE
Reflecting Connecticut’s Reality.
    COVID-19
    Vaccine Info
    Money
    Politics
    Education
    Health
    Justice
    More
    Environment
    Economic Development
    Gaming
    Investigations
    Social Services
    TRANSPORTATION
    Opinion
    CT Viewpoints
    CT Artpoints

LET�S GET SOCIAL

Show your love for great stories and out standing journalism
CT VIEWPOINTS -- opinions from around Connecticut

We aren’t ready for the next pandemic

  • CT Viewpoints
  • by Deena Mousa
  • February 5, 2021
  • View as "Clean Read" "Exit Clean Read"

At a time when we face greatest risk for pandemics, market incentives dissuade pharmaceutical investment in the development of vaccines.

Deena Mousa

As Sen. Bernie Sanders promises to “end… pharmaceutical industry greed,” the coronavirus rages. But Sanders isn’t quite right. The problem isn’t greed, it is the forces that drive pharmaceutical companies to innovate.

Pandemics are not just a scientific problem, they’re a financial one. We rely on markets to drive innovation in pharmaceuticals — and thus save lives. That system is broken. The way drug companies are rewarded for advances in vaccine technology discourages progress in how we produce vaccines.

Pandemics have a chilling effect not only on human health but also on the global economy, simultaneously stunting supply chains and reducing discretionary spending. As we travel more frequently and easily, the risks of pandemics and our vulnerability to them are only rising.

The most effective way of controlling the spread of viral infections is large-scale, immediate immunization. But current methods for manufacturing vaccines are slower and less effective than they could be.

Most flu vaccines are produced by injecting viruses into fertilized hen’s eggs and incubating them to allow the virus to replicate. Scientists later harvest the fluid from the eggs and inactivate the virus, a process that can take over six months. But this approach has its issues. After six months, the vaccine may be too late to stave off infection, or the virus used might not be the predominant strain anymore or have mutated.

Over the past decade, the U.S. government has invested billions of dollars to develop new eggless manufacturing technologies in order to produce vaccines more quickly. But there are good financial reasons pharmaceutical companies are slow to the mark. Although techniques that use mammalian cells are faster, more stable, and more effective than egg-based vaccine production, they are more expensive, and pharmaceutical companies have been hesitant to adopt them; they make up only about ten percent of influenza vaccines. Driven in part by high prices and an easier path to profit, pharmaceutical companies have instead increasingly focused resources on cancer and rare diseases.

Investment in vaccines is not nearly as lucrative because research and design costs are only recouped by vaccine sales when the outbreak occurs. But part of the value of vaccines that can mitigate future pandemic risks is their role as insurance against possible damage – even if the pandemic never happens. And the good a vaccine does is not simply in preventing that person from becoming sick, but in preventing them from infecting others. Further, selling vaccines earlier, when an outbreak has not yet spread substantially, means smaller profits for pharmaceutical companies than a delayed manufacturing process that might be complete at the peak of a pandemic.

One proposed solution is the Health Impact Fund. Rather than leaving pandemic prevention to the market, this system would compensate innovators with prizes proportional to the benefit of their drugs while setting the price of pharmaceuticals to the cost it takes to produce them. This would help incentivize research into drugs whose benefits are not necessarily rewarded through sales, including vaccines, while keeping prices low.

The more devastating a pandemic, the greater the profits to pharmaceutical companies — and markets don’t incentivize them to solve the problem. The result is palliative care, not a cure. The coronavirus may go away, but the threat of pandemics won’t. It’s time to ensure we are incentivizing drugmakers to play a larger role in addressing them.

Deena Mousa is a member of Yale’s Class of 2020.

CTViewpoints welcomes rebuttal or opposing views to this and all its commentaries. Read our guidelines and submit your commentary here.

Sign up for CT Mirror's free daily news summary.

ABOUT THE AUTHOR

SEE WHAT READERS SAID

RELATED STORIES
College students in Connecticut should be vaccinated now
by Dayna Vadala

If the state of Connecticut wants its institutions of higher learning to return to normal in the fall, it’s going to have to get shots into the arms of the students.

Connecticut, be a International leader against hair discrimination among children
by Faith D. Crittenden, Jade A. Anderson, MD, and Whitney L. Stuard

On March 1, 2020, Connecticut became the eighth state to pass the Crown Act, a national legislative movement that recognizes natural hair and cultural headwear discrimination as a form of racial discrimination in the workplace. While we are  in strong support and advocate for this law, it is important to recognize the limitations of the Crown Act and how it can be improved upon in future policy.

Three lessons for schools across America from Secretary Cardona’s hometown
by Mark Benigni

Over the past decade, Meriden Public Schools -- where U.S. Education Secretary Miguel Cardona served as assistant superintendent -- has become a unique laboratory for new ideas that push the boundaries of what is possible in public education. And many of those ideas have paid off.

A healthcare system too broken to fix
by Sosena Kedebe MD

On March 25, the White house announced that it was going to invest over $6 billion in health centers that are funded through the Resources and Services Administration (HRSA) in order to expand COVID-19 vaccinations and other health services provided to vulnerable populations. As a chief medical officer for a health center that is strained to reach some of the most disenfranchised patient population in Hartford, this was great news. Yet there was a part of me that took the news with a deep concern. Why you might ask?

The Connecticut Juvenile Training School and the lie that built it
by Colleen Shaddox 

Sitting in the paddy wagon, I was afraid – maybe apprehensive was a better word, since I rightly suspected that white privilege would guarantee me good treatment.  Still, I said a prayer of thanksgiving. After years of advocating for people in our carceral system, I was given a chance to develop more empathy.

Support Our Work

Show your love for great stories and outstanding journalism.

$
Select One
  • Monthly
  • Yearly
  • Once
Artpoint painter
CT ViewpointsCT Artpoints
Opinion College students in Connecticut should be vaccinated now
by Dayna Vadala

If the state of Connecticut wants its institutions of higher learning to return to normal in the fall, it’s going to have to get shots into the arms of the students.

Opinion Connecticut, be a International leader against hair discrimination among children
by Faith D. Crittenden, Jade A. Anderson, MD, and Whitney L. Stuard

On March 1, 2020, Connecticut became the eighth state to pass the Crown Act, a national legislative movement that recognizes natural hair and cultural headwear discrimination as a form of racial discrimination in the workplace. While we are  in strong support and advocate for this law, it is important to recognize the limitations of the Crown Act and how it can be improved upon in future policy.

Opinion Three lessons for schools across America from Secretary Cardona’s hometown
by Mark Benigni

Over the past decade, Meriden Public Schools -- where U.S. Education Secretary Miguel Cardona served as assistant superintendent -- has become a unique laboratory for new ideas that push the boundaries of what is possible in public education. And many of those ideas have paid off.

Opinion A healthcare system too broken to fix
by Sosena Kedebe MD

On March 25, the White house announced that it was going to invest over $6 billion in health centers that are funded through the Resources and Services Administration (HRSA) in order to expand COVID-19 vaccinations and other health services provided to vulnerable populations. As a chief medical officer for a health center that is strained to reach some of the most disenfranchised patient population in Hartford, this was great news. Yet there was a part of me that took the news with a deep concern. Why you might ask?

Artwork Grand guidance
by Anne:Gogh

In a world of systemic oppression aimed towards those of darker skintones – representation matters. We are more than our equity elusive environments, more than numbers in a prison and much more than victims of societal dispositions. This piece depicts a melanated young man draped in a cape ascending high above multiple forms of oppression. […]

Artwork Shea
by Anthony Valentine

Shea is a story about race and social inequalities that plague America. It is a narrative that prompts the question, “Do you know what it’s like to wake up in new skin?”

Artwork The Declaration of Human Rights
by Andres Chaparro

Through my artwork I strive to create an example of ideas that reflect my desire to raise social consciousness, and cultural awareness. Jazz music is the catalyst to all my work, and plays a major influence in each piece of work.”

Artwork ‘A thing of beauty. Destroy it forever’
by Richard DiCarlo | Derby

During times like these it’s often fun to revisit something familiar and approach things with a different slant. I have been taking some Pop culture and Art masterpieces and applying the vintage 1960’s and 70’s classic figures (Fisher Price, little people) to the make an amusing pieces. Here is my homage to Fisher -Price, Yellow […]

Twitter Feed
A Twitter List by CTMirror

Engage

  • Reflections Tickets & Sponsorships
  • Events
  • Donate
  • Newsletter Sign-Up
  • Submit to Viewpoints
  • Submit to ArtPoints
  • Economic Indicator Dashboard
  • Speaking Engagements
  • Commenting Guidelines
  • Legal Notices
  • Contact Us

About

  • About CT Mirror
  • Announcements
  • Board
  • Staff
  • Sponsors and Funders
  • Donors
  • Friends of CT Mirror
  • History
  • Financial
  • Policies
  • Strategic Plan

Opportunity

  • Advertising and Sponsorship
  • Speaking Engagements
  • Use of Photography
  • Work for Us

Go Deeper

  • Steady Habits Podcast
  • Economic Indicator Dashboard
  • Five Things

The Connecticut News Project, Inc. 1049 Asylum Avenue, Hartford, CT 06105. Phone: 860-218-6380

© Copyright 2021, The Connecticut News Project. All Rights Reserved. Website by Web Publisher PRO